The epidermal growth factor (EGF) receptor family network in cardiac hypertrophy and heart failure
- 1University of Reading
Abstract
The epidermal growth factor receptor (EGFR) network comprises 4 receptors (EGFR, ERBB2, ERBB3, ERBB4) and multiple ligands (EGFR-Ls; for example, AREG/EGF/TGFA that bind to EGFR, EREG/HBEGF that bind to EGFR/ERBB3, and NRG1 that binds to ERBB3/4). NRG1 and ERBB2/ERBB4 are cardioprotective, whilst other EGFR-Ls are implicated in cardiomyocyte hypertrophy. We sought to understand the importance of this network in human heart failure and development of cardiac hypertrophy. By mining data from the Human Protein Atlas, we established that the EGFR family and EGFR-Ls are expressed in different cardiac cells. Furthermore, EGFR-L mRNAs were modulated in failing vs non-failing human hearts implicating them in end-stage disease. In rat cardiomyocytes, EGFR-Ls all activated extracellular signal-regulated kinases 1/2 (ERK1/2) and Akt. However, NRG1 preferentially activated Akt whereas AREG/EREG/HBEGF/TGFA preferentially activated ERK1/2. EGF and NRG1 differentially regulated early gene expression with the response to NRG1 having a greater requirement for ERBB2. To determine if the network is involved in developing cardiac hypertrophy, mice were treated with angiotensin II (AngII) without/with afatinib (to inhibit all EGFR family members). Expression of EGFR-L mRNAs was modulated by AngII over 3-7d. At 7d, echocardiography and segmental strain analysis identified greater cardiac dysfunction in hearts from mice treated with afatinib/AngII compared with AngII alone, associated with inhibition of cardiomyocyte hypertrophy and enhanced cardiac fibrosis. In conclusion, the EGFR network plays an important role in cardiomyocyte and cardiac hypertrophy and is dysregulated in human failing hearts. Further insight into the network may enable identification of novel therapies for cardiac disorders.
Related
- ITACARE-P cardiorehab registry: real-world data on quality and outcomes in heart failure and ischaemic heart disease - a prospective observational study protocol of the Italian early post-acute cardiac rehabilitation network.
- Cardiac Reverse Remodeling and Clinical Outcomes Following Angiotensin Receptor‐Neprilysin Inhibitor Therapy in Heart Failure With Reduced Ejection Fraction
- Anthracycline Cardiotoxicity as Multicellular Network Failure: Cardiac Niche Reprogramming and Pathological Cell–Cell Communication
- Glutamine Metabolism in Cardiac Hypertrophy
- Gui Gan Shen Mai Yin attenuates cardiac hypertrophy and dysfunction in association with mitochondrial homeostasis and the PI3K/AKT1 signaling pathway
BibTeX
@misc{fuller2026epidermal,
title = {{The epidermal growth factor (EGF) receptor family network in cardiac hypertrophy and heart failure}},
author = {S. J. Fuller and S. T. Cooper and J. J. Cull and N. Adamczyk and C. Tapsell and R. Pokora and J. Spilletts and P. R. Dash and P. H. Sugden and A. Clerk},
howpublished = {bioRxiv},
year = {2026},
month = may,
doi = {10.64898/2026.05.16.724529},
url = {https://www.biorxiv.org/content/10.64898/2026.05.16.724529v2},
note = {CC BY},
}
RIS
TY - UNPB
TI - The epidermal growth factor (EGF) receptor family network in cardiac hypertrophy and heart failure
AU - S. J. Fuller
AU - S. T. Cooper
AU - J. J. Cull
AU - N. Adamczyk
AU - C. Tapsell
AU - R. Pokora
AU - J. Spilletts
AU - P. R. Dash
AU - P. H. Sugden
AU - A. Clerk
PY - 2026
DA - 2026/05/16
PB - bioRxiv
DO - 10.64898/2026.05.16.724529
UR - https://www.biorxiv.org/content/10.64898/2026.05.16.724529v2
AB - The epidermal growth factor receptor (EGFR) network comprises 4 receptors (EGFR, ERBB2, ERBB3, ERBB4) and multiple ligands (EGFR-Ls; for example, AREG/EGF/TGFA that bind to EGFR, EREG/HBEGF that bind to EGFR/ERBB3, and NRG1 that binds to ERBB3/4). NRG1 and ERBB2/ERBB4 are cardioprotective, whilst other EGFR-Ls are implicated in cardiomyocyte hypertrophy. We sought to understand the importance of this network in human heart failure and development of cardiac hypertrophy. By mining data from the Human Protein Atlas, we established that the EGFR family and EGFR-Ls are expressed in different cardiac cells. Furthermore, EGFR-L mRNAs were modulated in failing vs non-failing human hearts implicating them in end-stage disease. In rat cardiomyocytes, EGFR-Ls all activated extracellular signal-regulated kinases 1/2 (ERK1/2) and Akt. However, NRG1 preferentially activated Akt whereas AREG/EREG/HBEGF/TGFA preferentially activated ERK1/2. EGF and NRG1 differentially regulated early gene expression with the response to NRG1 having a greater requirement for ERBB2. To determine if the network is involved in developing cardiac hypertrophy, mice were treated with angiotensin II (AngII) without/with afatinib (to inhibit all EGFR family members). Expression of EGFR-L mRNAs was modulated by AngII over 3-7d. At 7d, echocardiography and segmental strain analysis identified greater cardiac dysfunction in hearts from mice treated with afatinib/AngII compared with AngII alone, associated with inhibition of cardiomyocyte hypertrophy and enhanced cardiac fibrosis. In conclusion, the EGFR network plays an important role in cardiomyocyte and cardiac hypertrophy and is dysregulated in human failing hearts. Further insight into the network may enable identification of novel therapies for cardiac disorders.
ER -